LT3294769T - Daugybinei mielomai (dm) skirtas gydymas - Google Patents

Daugybinei mielomai (dm) skirtas gydymas

Info

Publication number
LT3294769T
LT3294769T LTEP16723349.3T LT16723349T LT3294769T LT 3294769 T LT3294769 T LT 3294769T LT 16723349 T LT16723349 T LT 16723349T LT 3294769 T LT3294769 T LT 3294769T
Authority
LT
Lithuania
Prior art keywords
treatment
multiple myeloma
myeloma
Prior art date
Application number
LTEP16723349.3T
Other languages
English (en)
Inventor
Stéphane LECLAIR
Jan Endell
Stefan HÄRTLE
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of LT3294769T publication Critical patent/LT3294769T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
LTEP16723349.3T 2015-05-13 2016-05-13 Daugybinei mielomai (dm) skirtas gydymas LT3294769T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15167597 2015-05-13
PCT/EP2016/060810 WO2016180958A1 (en) 2015-05-13 2016-05-13 Treatment for multiple myeloma (mm)

Publications (1)

Publication Number Publication Date
LT3294769T true LT3294769T (lt) 2021-04-26

Family

ID=53174925

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16723349.3T LT3294769T (lt) 2015-05-13 2016-05-13 Daugybinei mielomai (dm) skirtas gydymas

Country Status (23)

Country Link
US (2) US10533057B2 (lt)
EP (1) EP3294769B1 (lt)
JP (2) JP7160533B2 (lt)
KR (1) KR20180008571A (lt)
CN (1) CN107614530A (lt)
AU (1) AU2016260895B2 (lt)
CA (1) CA2984464C (lt)
CY (1) CY1123982T1 (lt)
DK (1) DK3294769T3 (lt)
ES (1) ES2862708T3 (lt)
HR (1) HRP20210552T1 (lt)
HU (1) HUE054271T2 (lt)
IL (1) IL255552B (lt)
LT (1) LT3294769T (lt)
MX (1) MX2017014396A (lt)
PL (1) PL3294769T3 (lt)
PT (1) PT3294769T (lt)
RS (1) RS61668B1 (lt)
RU (1) RU2723047C2 (lt)
SG (1) SG11201708691VA (lt)
SI (1) SI3294769T1 (lt)
WO (1) WO2016180958A1 (lt)
ZA (1) ZA201708386B (lt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3294769T (lt) * 2015-05-13 2021-04-26 Morphosys Ag Daugybinei mielomai (dm) skirtas gydymas
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
KR20210002499A (ko) * 2018-03-28 2021-01-08 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
CA2329940A1 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
EP2799451A1 (en) 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
KR101472250B1 (ko) 2005-10-12 2014-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
CA2660356C (en) * 2006-08-07 2016-04-05 Pdl Biopharma, Inc. Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
US9040050B2 (en) * 2006-09-26 2015-05-26 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DK2580243T3 (da) * 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
HUE031956T2 (en) * 2010-09-27 2017-08-28 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and NHL
WO2014089279A1 (en) * 2012-12-05 2014-06-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rnf41 as a biomarker predicting response to lenalidomide in non-del(5q) mds
CN103421115B (zh) * 2013-09-02 2015-06-03 东南大学 一种cd38纳米抗体及应用
TN2016000142A1 (en) * 2013-10-31 2017-10-06 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers.
CN113134095A (zh) 2014-06-16 2021-07-20 梅约医学教育与研究基金会 治疗骨髓瘤
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
SG11201701867SA (en) 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
LT3294769T (lt) * 2015-05-13 2021-04-26 Morphosys Ag Daugybinei mielomai (dm) skirtas gydymas

Also Published As

Publication number Publication date
KR20180008571A (ko) 2018-01-24
ES2862708T3 (es) 2021-10-07
CY1123982T1 (el) 2022-05-27
CA2984464C (en) 2023-10-10
RU2017137496A (ru) 2019-06-13
SG11201708691VA (en) 2017-11-29
US20190048091A1 (en) 2019-02-14
EP3294769B1 (en) 2021-01-13
MX2017014396A (es) 2018-03-23
EP3294769A1 (en) 2018-03-21
RU2017137496A3 (lt) 2019-06-13
ZA201708386B (en) 2019-06-26
DK3294769T3 (da) 2021-03-08
AU2016260895A1 (en) 2017-11-09
JP2021130668A (ja) 2021-09-09
CN107614530A (zh) 2018-01-19
PT3294769T (pt) 2021-04-13
WO2016180958A1 (en) 2016-11-17
HUE054271T2 (hu) 2021-08-30
PL3294769T3 (pl) 2021-07-05
RU2723047C2 (ru) 2020-06-08
JP2018515513A (ja) 2018-06-14
JP7160533B2 (ja) 2022-10-25
IL255552B (en) 2022-01-01
HRP20210552T1 (hr) 2021-05-14
IL255552A (en) 2018-01-31
US10533057B2 (en) 2020-01-14
SI3294769T1 (sl) 2021-07-30
US11591406B2 (en) 2023-02-28
CA2984464A1 (en) 2016-11-17
RS61668B1 (sr) 2021-04-29
AU2016260895B2 (en) 2021-08-05
US20200079871A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
SG11201705093UA (en) Composition for treating il-6-related diseases
IL278247B (en) mct4 inhibitors to treat the disease
GB2544294B (en) Goggles for snowsports
IL256116B (en) geometric
HK1244217A1 (zh) 用於治療蛋白質病的方法
HK1253238A1 (zh) 用於治療疾病的gls1抑制劑
HK1255871A1 (zh) 用於治療骨髓瘤的賽度替尼
GB201522243D0 (en) Treatment
HK1257338A1 (zh) 用於治療多發性骨髓瘤的btk抑制劑組合
HK1250649A1 (zh) 用於治療白血病的抗-s100a8
GB201502137D0 (en) Treatment
ZA201708386B (en) Treatment for multiple myeloma (mm)
GB201519450D0 (en) Novel treatment
GB201519331D0 (en) Treatment paradigm
GB201508841D0 (en) Treatment
IL254336A0 (en) A new treatment method
GB201604658D0 (en) Treatment for pain
HK1254378A1 (zh) [(2-乙氧基-5-反式-1-丙烯-1-基)-苯氧基]封端化合物
GB201503008D0 (en) Treatment
HUP1700275A2 (en) Process for self-host
GB201518349D0 (en) Treatment
GB201515739D0 (en) Treatment
GB201514008D0 (en) Treatment
GB201511517D0 (en) Treatment system
GB201505205D0 (en) Treatment for pain